Skip to main content
. 2020 Jun 16;2(8):e465–e473. doi: 10.1016/S2665-9913(20)30170-3

Figure 1.

Figure 1

Clinical outcome measures in the mavrilimumab group versus the control group

(A) Cumulative survival estimated by a Kaplan-Meier curve at 28 days and compared with a Fisher's exact test. (B) Mechanical ventilation-free survival estimated by a Kaplan-Meier curve and compared with a log-rank test. (C) Time to clinical improvement estimated by a Kaplan-Meier curve and compared with a log-rank test. (D) Time to fever resolution estimated by a Kaplan-Meier curve and compared with a log-rank test.